Welcome To RobinsPost.com


Related News Videos From Youtube For:

3 Biggest Healthcare Stories At #JPM19 This Year

Every year, thousands descend upon San Francisco from all over the world to hear the latest corporate updates from healthcare's most important companies. The event, which is organized by J.P. Morgan, is often used to unveil market-moving news and this year's conference was no disappointment: Bristol-Myers Squibb (NYSE: BMY) announced a mega-deal for biotech Goliath Celgene (NASDAQ: CELG). Eli Lilly (NYSE: LLY) acquired precision-cancer drug developer Loxo Oncology (NASDAQ: LOXO) for $8 billion. And Sage Therapeutics (NASDAQ: SAGE) rolled out impressive data for a postpartum depression drug. In this episode of The Motley Fool's Industry Focus: Healthcare, Todd Campbell joins analyst Shannon Jones to explain why Bristol-Myers and Loxo Oncology are doing their deals and how Sage Therapeutics hopes to reshape how doctors treat depression. Tune in to learn if Celgene's stock is still worth buying, Loxo Oncology can provide the spark Eli Lilly needs, and if Sage Therapeutics has a blockbuster drug on its hands. ------------------------------------------------------------------------ Subscribe to The Motley Fool's YouTube Channel: http://www.youtube.com/TheMotleyFool Or, follow our Google+ page: https://plus.google.com/+MotleyFool/posts Inside The Motley Fool: Check out our Culture Blog! http://culture.fool.com Join our Facebook community: https://www.facebook.com/themotleyfool Follow The Motley Fool on Twitter: https://twitter.com/themotleyfool

Why Adobe is My Top Stock to Buy for 2019

The most important lesson from 83,000 brain scans | Daniel Amen | TEDxOrangeCoast

55, unemployed and faking normal: One woman's story of barely scraping by

Outlook Therapeutics over 50% enrolled in clinical study to treat wet AMD

Medtronic CEO Omar Ishrak on Mazor X acquisition

The mathematician who cracked Wall Street | Jim Simons

2019 WMIF | Last Mile: Fully Implementing AI in Healthcare

Forbes Healthcare Summit 2018: John Doerr | Full Panel | Forbes Live

How To Invest in Drug Companies Seeking FDA Approval

Aswath Damodaran: "Valuation: Four Lessons to Take Away" | Talks at Google